Oncology Pipeline
Artios Pharma Raises $115 Million Series D to Advance DNA Damage Response Cancer Therapies
Artios Pharma; Series D financing; DNA Damage Response (DDR); cancer therapies; alnodesertib; ART6043; oncology pipeline; pancreatic cancer; colorectal cancer; breast cancer; investors; clinical trials
GSK Secures Exclusive Rights to Syndivia’s Preclinical Prostate Cancer ADC in $357 Million Deal
GSK; Syndivia; ADC; prostate cancer; metastatic castration-resistant prostate cancer; exclusive licensing; oncology pipeline; GeminiMab technology; milestone payments; preclinical asset
Ipsen to Acquire ImCheck Therapeutics for €350 Million to Expand Immunotherapy Pipeline
Ipsen; ImCheck Therapeutics; acquisition; €350 million; €1 billion deal; immunotherapy; oncology pipeline; butyrophilin superfamily; ICT01; acute myeloid leukemia; monoclonal antibody; BTN3A
BioNTech and DualityBio Achieve Phase 3 Success with ADC Therapy for HER2-Positive Breast Cancer, Advancing Oncology Pipeline
BioNTech; DualityBio; antibody-drug conjugate (ADC); HER2-positive breast cancer; trastuzumab pamirtecan; BNT323/DB-1303; phase 3 trial; progression-free survival; oncology pipeline; ADC market
Bayer Expands Oncology Pipeline with $1.3B Kumquat Deal
Bayer; Kumquat Biosciences; oncology pipeline; KRAS G12D inhibitor; FDA approval; cancer therapy; precision oncology; commercialization; milestone payments
Jazz Pharmaceuticals to Acquire Chimerix for $935 Million, Gaining Promising Brain Tumor Drug Dordaviprone
Jazz Pharmaceuticals, Chimerix, Acquisition, Dordaviprone, Brain tumor, H3 K27M-mutant diffuse glioma, FDA approval, Oncology pipeline
Eli Lilly Acquires Scorpion Therapeutics for Up to $2.5 Billion to Bolster Oncology Pipeline
Eli Lilly, Scorpion Therapeutics, PI3Kα inhibitor, STX-478, cancer treatment, oncology pipeline, acquisition, biotech deal
Eli Lilly Acquires Scorpion Therapeutics in $2.5 Billion Deal to Boost Breast Cancer Treatment Options
Eli Lilly, Scorpion Therapeutics, breast cancer, PI3Kα inhibitor, STX-478, oncology pipeline, targeted therapy
HUTCHMED Divests 45% Stake in Shanghai Hutchison Pharmaceuticals for $608 Million to Focus on Core Oncology Pipeline
HUTCHMED, Shanghai Hutchison Pharmaceuticals, divestment, oncology pipeline, antibody-targeted therapy conjugates (ATTCs), strategic focus, profitability.
Pfizer’s Next Challenge: Phase 3 Trials for Breakthrough Cancer Therapies
Pfizer, Phase 3 trials, cancer therapies, oncology pipeline, clinical trials